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Lucia Manzanas,10 Jaume Crespı́,11 and Roberto Gallego12
1Hospital Universitari Vall d’Hebron, Barcelona, Spain
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Objectives. To evaluate efficacy and safety of an aflibercept treat-and-extend (TAE) regimen in patients with macular oedema
(MO) secondary to central retinal vein occlusion (CRVO). Design, Setting, and Patients. Phase IV, prospective, open-label,
single-arm trial in 11 Spanish hospitals. Treatment-naı̈ve patients with <6 month diagnosis of MO secondary to CRVO and
best-corrected visual acuity (BCVA) of 73-24 ETDRS letters were included between 23 January 2015 and 17 March 2016.
Intervention. Intravitreal aflibercept 2 mg monthly (3 months) followed by proactive individualized dosing.Main Outcomes.
Mean change in BCVA after 12 months. Results. 24 eyes (24 patients) were included; mean (SD) age: 62.8 (15.0) years; 54.2%
male; median (IQR) time since diagnosis: 7.6 (3.0, 15.2) days. Mean BCVA scores significantly improved between baseline
(56.0 (16.5)) and Month 12 (74.1 (17.6)); mean (95% CI) change: 14.8 (8.2, 21.4); P � 0.0001. Twelve (50.0%) patients gained
≥15 ETDRS letters. Foveal thickness improved between baseline (mean: 569.4 (216.8) µm) and Month 12 (mean 257.4
(48.4) µm); P< 0.0001. At Month 12, 8.3% patients had MO. *e mean (SD) number of injections: 8.3 (3.0). No treatment-
related AEs were reported. Five (20.8%) patients experienced ocular AEs. Two nonocular serious AEs were reported.
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1. Introduction
Retinal vein occlusion (RVO) is thought to result from
a thrombotic event or vessel wall pathology that can severely
impact visual acuity [1, 2]. Macular oedema (MO) secondary
to RVO is the second-most common retinal vascular disease
after diabetic retinopathy and is subdivided into central
retinal vein occlusion (CRVO) and branch retinal vein
occlusion (BRVO) based on the location of the occlusion [3].
Central retinal vein occlusion is estimated to affect be-
tween 0.3% and 2.1% of the global population with no
significant variation in prevalence due to ethnicity or gender
[4]. Like BRVO, clinical features of CRVO include dilated
and tortuous retinal veins, deep and superficial retinal
haemorrhages, cotton wool spots, and retinal oedema [5].
However, unlike BRVO, these features are found in all
quadrants of the retina in CRVO. Visual loss after CRVO
commonly occurs as a result of MO, ischemia, or in more
advanced stages, occurs as a result of vitreous haemorrhage
or neovascularisation.
Current therapeutic options for the treatment of MO
secondary to CRVO include laser photocoagulation, vas-
cular endothelial growth factor (VEGF) inhibitors, and
intraocular steroids [6]. Several recent meta-analyses have
shown treatment of MO secondary to CRVO with anti-
VEGF agents resulted in improved best-corrected visual
acuity (BCVA) over time and fewer adverse events com-
pared to placebo, corticosteroids, or laser photocoagulation
[7–9]. An assessment of clinical evidence by the American
Academy of Ophthalmology concluded that anti-VEGF
pharmacotherapy was safe and effective over two years
for MO secondary to CRVO [10]. Network meta-analysis of
drug treatments to manage MO secondary to CRVO found
no evidence of differences in efficacy between the anti-VEGF
agents: ranibizumab, aflibercept, bevacizumab, or cortico-
steroid triamcinolone [11].
*e recombinant fusion protein aflibercept (Eylea;
Regeneron Pharmaceuticals), a fusion protein of key do-
mains from human VEGF receptors 1 and 2, was approved
by the US Food andDrug Administration (FDA) in 2011 and
by the EuropeanMedicines Agency in 2012 for the treatment
of patients with neovascular age-related macular de-
generation (nAMD) [12, 13]. A higher VEGF affinity and
a longer half-life compared to older anti-VEGF agents re-
duce the frequency of intravitreal (IVT) injections needed to
maintain therapeutic effect, thus potentially reducing the
clinical burden placed on patients by reducing the number of
treatment visits [14–18].
*e findings of the sister confirmatory phase III rand-
omised controlled GALILEO and COPERNICUS trials
showed IVT aflibercept improved 12-month visual and
anatomical outcomes when administered pro re nata (PRN)
following six monthly injections in patients with MO sec-
ondary to CRVO, provided that the patients were admin-
istered aflibercept following the initial event [5, 19, 20].
*e treat-and-extend (TAE) regimen is a proactive in-
dividualized treatment regimen designed to maximize the
benefit to risk ratio of anti-VEGF agents. It is frequently used
for the treatment of nAMD [21–23]. Compared to fixed dose
and PRN regimens, the TAE regimen reduces treatment
burden and does not require disease reactivation for con-
tinued treatment [23]. Under this regimen, anti-VEGF
agents are administered as fixed loading doses until clini-
cal remission, followed by increasing treatment intervals
until a maximal safe interval is reached (usually 10–12
weeks). Treatment intervals are shortened by two weeks if
there are any negative changes in clinical parameters. Recent
studies of ranibizumab or bevacizumab have shown the TAE
regimen to be suitable for the treatment of diabetic MO and
MO secondary to CRVO over one year [24, 25].
*e objective of this study was to prospectively evaluate
the 12-month efficacy and safety of an aflibercept TAE
regimen in patients with MO secondary to CRVO.
2. Methods
2.1. Trial Design. *is phase IV, prospective, open-label,
single-arm, multicentre trial was conducted in 11 trial
sites (tertiary healthcare facilities located in the Basque
Country, Castille and León, Catalonia, Madrid, and Valencia
autonomous communities) in Spain (NEUTON Trial (RET-
AFLI-2014-01); EudraCT Number: 2014-000975-21). *e
trial was conducted in accordance with the ethical principles
of the declaration of Helsinki and Good Clinical Practice
guidelines. All ethics committees approved the trial protocol
and its amendments.
2.2. Patients. *e main inclusion criteria were as follows:
willingness to provide informed consent; aged ≥18 years;
a diagnosis of MO secondary to RCVO within the last six
months with mean central subfield thickness of ≥250 µm
(spectral-domain optical coherence tomography (SD-
OCT)); a baseline BCVA score in the study eye of be-
tween 73 and 24 early treatment diabetic retinopathy study
(ETDRS) letters (inclusive) measured using the ETDRS
chart at four meters (Snellen equivalent: 20/40 to 20/320);
a baseline BCVA score of greater ≥20/400 in the Snellen
optotype (0.05 decimal, 1 line of sight) in the contralateral
eye; the absence of cataracts or other eye diseases that may
affect visual acuity.
*e main exclusion criteria (in the study eye) were as
follows: prior anti-VEGF treatment, photodynamic therapy,
corticosteroid treatment or thermal laser treatment; in-
traocular surgery (including cataract surgery) within three
months prior to first aflibercept administration; scarring,
fibrosis or atrophy that affects the centre of the fovea;
ruptures/tears in the pigmentary retinal epithelial that affect
the fovea; severe proliferative macular ischemia or iris
rubeosis; prior vitrectomy, submacular surgery or any other
surgical procedure for nAMD; or active intraocular in-
flammation in the study eye.
2.3. Trial Interventions. During the loading phase (first three
months), IVT aflibercept 2mg (40mg/ml) was given once
monthly (Week 0, 4, and 8). If the patient improved or
showed signs of BCVA stability (no change or a decrease of
<5 EDTRS letters during three consecutive evaluations)
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and/or visual and morphological outcomes (an increase of
≥50 µm central retinal thickness with the absence of new
cystic alterations or subretinal fluid or the absence of per-
sistent or recurrent exudation (intraretinal/subretinal) by
SD-OCT) after three consecutive visits (Week 4, 8, and 12),
the TAE phase began six weeks thereafter (at Week 18). *e
treatment window was extended by two weeks per visit if no
evidence of disease activity was observed (in relation to the
period since the last visit) for a maximum of 12 weeks. If
there were signs of disease, the patient was retreated and the
next visit was scheduled for four weeks later. *e trial
concluded at the end-of-trial (EOT) visit at Month 12.
2.4. Trial Procedures. At baseline eligibility criteria, de-
mographic data, medical history, physical examination,
concomitant medication, pregnancy test (if applicable),
intraocular pressure (IOP), BCVA score, SD-OCT, fundus
fluorescein angiography (FA), retinography, eye fundus
photography, and adverse events (AEs) were assessed or
reported. During the loading phase (Month 0–2; Week 0–8),
TAE phase (Month 3–12; Weeks 12–48), and EOT visit
(Month 12; Week 52) concomitant medication, IOP, BCVA,
SD-OCT, FA imaging, and AEs were assessed or reported.
All FA images and retinographies were sent to the Instituto
Oftalmológico Gómez-Ulla reading centre (Responsible
reader: Francisco Gómez-Ulla). Optical coherence tomog-
raphy assessments were performed using Zeiss® (Cirrusversion 4.0 or higher), Topcon® (3D, 2000 or 2000 plus), orHeidelberg® (Spectralis version 5.1 or higher) SD-OCTimaging devices, dependent on availability at each trial
site. Patients were evaluated with the same device for the
duration of the trial.
2.5. Trial Outcomes. *e primary outcome was mean
change in BCVA (ETDRS letters) between baseline and
Month 12 (EOT) visit. Secondary outcomes included
proportion of patients gaining ≥15 ETDRS letters at
Month 12; mean change in BCVA at Month 3 (Week
12–14, after loading doses) versus baseline; mean changes
in foveal thicknesses (SD-OCT) at months 3 and 12 versus
baseline; proportion of patients free of MO (SD-OCT;
central foveal thickness < 200 µm) at Months 3 and 12;
mean number of injections; and proportion of patients not
requiring additional TAE injections. Safety outcomes in-
cluded ocular and nonocular AEs and serious AEs (SAEs).
Key nonocular adverse events were considered to be those
defined by the Antiplatelet Trialists’ Collaboration as
Arteriothrombolic Events (APTC ATE) [26].
2.6. Sample Size and Statistical Analysis. Based on the 1-year
results from the GALILEO trial (mean change in BCVA of
16.9 ETDRS letters in patients with MO secondary to CRVO
receiving aflibercept every month for 20 weeks followed by
PRN thereafter) [19], a total of 43 patients was estimated to
detect a significant mean change in BCVA at 12 months with
95% power, a significance level (alpha) of 0.01, and
a standard deviation of 25 letters. Estimating a 15% loss to
follow-up, a sample size of 50 patients was planned.
*e intention-to-treat (ITT) population used for all
efficacy analyses included all patients enrolled in the trial
who had received at least one dose of aflibercept and who
had undergone at least one postbaseline BCVA assessment.
*e safety population used for all safety analyses included all
patients who had received at least one dose of aflibercept.
All data were descriptively analysed. Continuous vari-
ables were presented with the number of observations,
mean, 95% confidence interval (CI) for the mean, median,
standard deviation (SD), and interquartile range (IQR).
Categorical variables, however, were described in terms of
frequencies and percentages. Changes from baseline were
analysed using McNemar’s tests for categorical variables and
parametric (Student’s t-test for paired data) or non-
parametric (Wilcoxon signed-rank test) tests for continuous
variables, as applicable. *e level of significance used for all
tests was 0.05 (two-tailed). No imputation for missing data
was performed.
Data analysis was performed using the SAS® statisticalpackage for Windows (version 9.4, SAS Institute Inc., Cary,
U.S.).
3. Results
3.1. Patient Disposition and Baseline Characteristics. A total
of 31 eyes from 31 patients were screened for trial inclusion,
and 24 eyes from 24 patients were enrolled in the trial
between 23 January 2015 and 17 March 2016. Eighteen
(58.6%) patients completed the 12 months of follow-up; two
(8.3%) patients discontinued due to a withdrawal of consent,
one (4.2%) due to a protocol deviation, one (4.2%) due to
a loss of visual acuity without MO, one (4.2%) lost to follow-
up, and one (4.2%) withdrawn due to not meeting all eli-
gibility criteria.
Baseline characteristics are shown in Table 1.*emean±
SD age at trial inclusion was 62.8± 15.0 years, and 54.2%
were male. Median (IQR) time since diagnosis was 7.6 (3.0,
15.2) days with a mean± SD intraocular pressure (IOP) of
15.7± 3.0mmHg. Arterial hypertension and dyslipidaemia
were the most common medical history or concomitant
pathologies.
3.2. BCVA at Month 12. *e mean± SD baseline BCVAs in
the study and contralateral eye were 56.0± 16.5 and 81.0±
9.3 ETDRS letters, respectively (Tables 1 and 2). At Month
12, mean± SD BCVA in the study eye was 74.1± 17.6,
corresponding to amean (95%CI) increase of 14.8 (8.2, 21.4)
ETDRS letters (P � 0.0001) (Table 2).
3.3. Secondary Endpoints. *e mean± SD BCVA after the
three monthly aflibercept IVT loading doses was 70.8± 19.6,
a mean (95% CI) increase of 14.0 (7.8, 20.2) ETDRS letters
(P � 0.0001) (Table 2). Analysis of BCVA over time showed
a relatively stable improvement in BCVA after three months
that was maintained over follow-up until Month 12
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(Table 2). Twelve (50.0%) patients gained ≥15 ETDRS letters
by Month 12.
Mean± SD foveal thickness decreased from 569.4±
216.8 µm at baseline to a mean (95% CI) of 291.9 (223.1,
360.7) at Month 3, a significant reduction of 272.2 (167.0,
377.4) µm (P< 0.0001) (Table 2). AtMonth 12, the reduction
in foveal thickness was 296.0 (196.8, 395.1) µm (P< 0.0001).
Nineteen (79.2%) patients did not exhibit signs of MO at
Month 3 or Month 12 (Table 2). One (4.2%) patient con-
tinued to exhibit MO for the duration of the study, one
(4.2%) patient resolved during the TAE phase, and one
(4.2%) patient temporarily resolved during the loading phase
but relapsed during the TAE phase.
3.4. Exposure to Aflibercept. Twenty-two (91.7%) patients
completed the loading phase (three aflibercept injections);
one (4.2%) patient was withdrawn after receiving one in-
jection, and one (4.2%) patient was lost to follow-up after
receiving two injections. A mean± SD of 8.3± 3.0 aflibercept
injections were received by patients during the trial (Table 2)
with 14 (58.3%) receiving ≤8 injections (Figure 1).
3.5. Safety. Overall, one (4.2%) patient experienced a non-
fatal APTC ATE event (stroke) of moderate severity that was
unrelated to study treatment, required hospitalisation pro-
longation, and was resolved by the end of the study (Table 3).
*e same patient also experienced a SAE (lung neoplasm
surgery) that was of moderate severity, unrelated to study
treatment, but required hospitalisation prolongation.
Nonserious ocular AEs were experienced by five (20.8%)
Table 1: Baseline characteristics.
ITTpopulation (N � 24)
Baseline characteristics
Age (years), mean (SD) 62.8 (15.0)
Male, N (%) 13 (54.2)
Caucasian ethnicity, N (%) 24 (100.0)
Time from MO secondary to CRVO
diagnosis (days), median (IQR) 7.6 (3.0, 15.2)
IOP in study eye (mmHg), mean (SD) 15.7 (3.0)
Baseline BCVA score (ETDRS) in
contralateral eye, letters, mean (SD) 81.0 (9.3)
Patients with any relevant medical
history/concomitant pathology 23 (95.8)




Diabetes mellitus 3 (12.5)
Obesity 3 (12.5)
Others∗ 17 (70.8)
BCVA: best-corrected visual acuity; CRVO: central retinal vein occlusion;
ETDRS: early treatment diabetic retinopathy study; IOP: intraocular
pressure; IQR: interquartile range; ITT: intention-to-treat; MO: macular
oedema; SD: standard deviation. ∗Conditions experienced by <10% of the
patient population.
Table 2: BCVA and secondary endpoints after loading






BCVA score (ETDRS letters)
Week 0 (baseline), N 24
Mean (SD) score 56.0 (16.5)
Month 3, N 21
Mean (SD) score 70.8 (19.6)
95% CI 61.9, 79.7
Mean (95% CI) change from
baseline 14.0 (7.8, 20.2) 0.0001
Month 12 (EOT), N 21
Mean (SD) score 74.1 (17.6)
95% CI 66.1, 82.1
Mean (95% CI) change from
baseline 14.8 (8.2, 21.4) 0.0001
Proportion gaining ≥15 ETDRS letters
at EOT, N (%)
Yes 12 (50.0)
No 9 (37.5)
Not available 3 (12.5)
Retinal (foveal) thickness
by SD-OCT (μm)
Week 0 (baseline), N 24
Mean (SD) score 569.4 (216.8)
Month 3, N 21
Mean (SD) score 291.9 (151.2)
95% CI 223.1, 360.7




Month 12 (EOT), N 21
Mean (SD) score 257.4 (48.4)
95% CI 235.4, 279.5






Week 0 (baseline), N 24
Yes 24 (100.0)
Month 3, N 21
Yes 2 (8.3)
No 19 (79.2)
Month 12 (EOT), N 21
Yes 2 (8.3)
No 19 (79.2)
Exposure: number of aflibercept
injections
Number of injections
Mean (SD) 8.3 (3.0)
Median (IQR) 8.0 (8.0, 10.5)
TAE injection interval (weeks)
Mean (SD) 7.0 (2.2)
Median (IQR) 6.1 (5.2, 9.1)
BCVA: best-corrected visual acuity; ETDRS: early treatment diabetic
retinopathy study; EOT: end of trial; IQR: interquartile range; ITT: in-
tention-to-treat; MO: macular oedema; SD: standard deviation; SD-OCT:
spectral-domain optical coherence tomography. TAE: treat-and-
extend. ∗All values compared to baseline using Student’s t-test for paired
samples.
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patients; the most severe AE was vitreous detachment of
moderate severity that had not resolved at the end of the
study. One (4.2%) patient experienced two ocular AEs
(aggravated cataracts and epiretinal membrane), both of
mild severity and both not resolved at the end of the study.
With regard to systemic AEs, nine (37.5%) patients expe-
rienced at least one AE; only one AE (bronchitis) was re-
ported for over one patient—both patients experienced
bronchitis of mild severity that was resolved by the end of the
study.
4. Discussion
Currently, TAE regimens are increasingly used in daily
practice for the management of exudative macular diseases
to the detriment of fixed and PRN regimens. On one hand,
the main advantages of TAE are: (1) proactive treatment that
avoids further retinal cells damage derived from disease
recurrence, (2) reduction in the number of monitoring visits,
(3) predictability of the treatment administration both for
the patient and the ophthalmologist, (4) customized treat-
ment for every patient enabling to know the time of the
reactivation of the disease. In addition, TAE offers better
anatomical and visual results in comparison with PRN
regimens and equivalent results with fixed either monthly or
bimonthly treatment regimens [21, 27]. However, one of the
main concerns that has been raised is that a prolonged TAE
could induce an overtreatment with potential unknown side
effects if a dry macula is repeatedly injected over time.
Likewise, it has not been clearly defined the optimal moment
to interrupt the TAE treatment.
*e most recommended TAE regimen is based on
a gradual two-week extension interval in the absence of
disease activity with a maximal extension of 12 weeks [21].
*e extension should be initiated after a loading phase
consisting of three consecutive monthly injections. Never-
theless, there is no total consensus about this since some
ophthalmologists prefer to initiate the extension after the
first injection or after a loading phase of two injections. In
the present study, we decided to use a loading phase of three
injections to try to maximize an initial visual gain that could
be maintained with the subsequent TAE during all the study
duration.
Confirmatory phase III randomised, controlled trials
have shown monthly followed by PRN IVT aflibercept
resulting in improved visual and anatomical outcomes in
patients with MO secondary to CRVO; however, it remains
unknown whether similar improvements could be main-
tained under a TAE regimen [4, 19, 20]. In this trial,
a significant mean 14 ETDRS letter improvement in BCVA
was recorded at the end of the loading phase (Month 3) that
was followed by a peak BCVA improvement of 14.8 ETDRS
letters at the end of the TAE regimen (Month 12). *ese
findings are consistent with the results from the GALILEO
(N � 103) and COPERNICUS (N � 115) trials which ob-
served peak BCVA improvements of 18.0 and 17.3 ETDRS
letters, respectively, after the six monthly aflibercept doses
(primary endpoint) that were maintained at 12 months
following a PRN regimen (16.9 and 16.2 ETDRS letter
improvement, respectively) [19, 20]. Further similarity can
be found in the retrospective study by Rahimy et al. where
initial gains in BCVA at three months were maintained at 12
1 (4.2%) 1 (4.2%) 1 (4.2%) 1 (4.2%) 1 (4.2%)
9 (37.5%)
4 (16.7%) 4 (16.7%)


















Figure 1: Number of aflibercept injections received by patients during the trial.
Table 3: Summary of adverse events.
Safety population
(N � 24) N (%)
Serious adverse events (SAEs)
Nonfatal APTC ATE events
(not related to trial treatment) 1 (4.2)
Stroke 1 (4.2)
Other nonfatal SAEs 1 (4.2)
Systemic (nonocular; not related
to trial treatment)
Lung neoplasm surgery 1 (4.2)
Adverse events (AEs)
Nonserious ocular AEs
(not related to trial treatment) 5 (20.8)
Keratitis 2 (8.3)
Vitreous detachment 2 (8.3)
Aggravated cataract 1 (4.2)
Epiretinal membrane 1 (4.2)
Hyposphagma 1 (4.2)
Increased intraocular pressure 1 (4.2)
Nonserious systemic (nonocular)
AEs (not related to trial treatment)∗ 9 (37.5)
Bronchitis 2 (8.3)
APTC ATE: antiplatelet trialists’ collaboration arteriothrombolic event.
∗AEs experienced by >1 patient presented.
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months in patients with MO secondary to CRVO treated
with IVT bevacizumab or ranibizumab under a TAE regi-
men [25].
Despite comparable improvements in BCVA, the pro-
portion of patients in whom a vision gain of ≥15 letters was
exhibited at Month 12 (N � 12, 50%) was less than the
proportions reported in the GALILEO (N � 62, 60.2%) and
COPERNICUS trials (N � 115; 55.3%) [19, 20]. Given the
small sample size in the present study, it is unclear whether
this disparity is significant and clinically relevant. Differ-
ences in study design, such as loading phase duration or data
analysis (last observation carried forward approach used for
data analysis in the two phase III trials vs. no imputation in
this study), may account for or contribute to the observed
difference.
Anatomical changes in retinal thickness showed a similar
pattern of improvement as BCVA, with a significant re-
duction in foveal thickness occurring after the loading phase
that was maintained at Month 12. *e mean reduction in
central retinal (foveal) thickness at Month 3 (mean: 272.2 µm
reduction) was less than the overall 448.6 µm and 457.2 µm
reductions observed at the end of the sixmonthly injections in
the GALILEO and COPERNICUS studies, respectively
[19, 20]. While the magnitude of the reduction was smaller in
the present study, most likely due to the fewer monthly
aflibercept injections, in all trials, these anatomical im-
provements were maintained at Month 12. Further contrast
can be observed compared to TAE bevacizumab or ranibi-
zumab, where reductions in central retinal thickness were
continual over the course of 12 months, albeit with a final
reduction similar to that presented here at Month 3 [25].
Overall, the proportion of patients with MO decreased
by 90.5% (N � 19) by Month 3, with a similar proportion
reported at Month 12; one patient exhibited recurrent MO
while another resolved during the TAE phase. As only two
patients had unresolved MO by the EOT visit, no com-
parison of baseline characteristics yield insight into possible
contributing factors for this observation.
Exposure to aflibercept was measured by the number of
injections, duration of treatment, and the proportion of
patients requiring further treatment after receiving the
loading doses. *e mean (SD) injection interval during the
TAE phase was 7.0 (2.2) weeks. *e overall mean number of
injections was similar to the mean number of bevacizumab
or ranibizumab injections when administered on a TAE
regimen [25]. *is contrasts with the GALILEO and
COPERNICUS trials where a respective mean number of
11.8 and 9.9 injections were administered during the first
year; however, this is likely attributable to the treatment
regimen (six monthly doses followed by PRN) [19, 20].
In terms of safety, two SAEs were reported during the
study in one patient. *e patient experienced a stroke and
lung neoplasm surgery, neither of which were related to trial
treatment. *e absence of ocular SAEs was in contrast to
both the GALILEO and COPERNICUS trials, which re-
ported a respective 1.9% (N � 2) and 3.5% (N � 4) of pa-
tients experienced ocular SAEs when aflibercept was injected
monthly (weeks 0–24) and 8.2% (N � 8) and 2.7% (N � 3)
of patients when aflibercept was injected PRN (weeks 24–52)
[19, 20]. Furthermore, no nonserious AEs related to treat-
ment were reported, either systemic or ocular AEs. *e
proportion of patients who experienced nonserious ocular
AEs in this trial was lower than that reported in the
GALILEO trial where 54.8% (between weeks 0–24) and
69.1% (weeks 24–52) of patients receiving aflibercept re-
ported at least one ocular AE [19].
*e shortcomings of this trial include the small number
of patients enrolled and the absence of a control group,
which limit any conclusions being drawn.
5. Conclusion
*e present trial suggests that aflibercept is efficacious in
patients with MO secondary to CRVO when treated with
a TAE regimen.*e low incidence of ocular AEs suggests the
TAE regimen may be preferable over other treatment reg-
imens. Studies in larger cohorts of patients with MO sec-
ondary to CRVO should be carried out in order to confirm
the results of this trial.
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